{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:48:23Z","timestamp":1782100103118,"version":"3.54.5"},"reference-count":295,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006087","name":"Direcci\u00f3n General de Asuntos del Personal Acad\u00e9mico, Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"crossref","award":["IV-201220 (CV-201220)"],"award-info":[{"award-number":["IV-201220 (CV-201220)"]}],"id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["366135"],"award-info":[{"award-number":["366135"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["707238"],"award-info":[{"award-number":["707238"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["749447"],"award-info":[{"award-number":["749447"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["717832"],"award-info":[{"award-number":["717832"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["589949"],"award-info":[{"award-number":["589949"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["394569"],"award-info":[{"award-number":["394569"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"crossref","award":["508395"],"award-info":[{"award-number":["508395"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"crossref","award":["388590"],"award-info":[{"award-number":["388590"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Microb Cell Fact"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>SARS-CoV-2 is a novel \u03b2-coronavirus that caused the COVID-19 pandemic disease, which spread rapidly, infecting more than 134 million people, and killing almost 2.9 million thus far. Based on the urgent need for therapeutic and prophylactic strategies, the identification and characterization of antibodies has been accelerated, since they have been fundamental in treating other viral diseases. Here, we summarized in an integrative manner the present understanding of the immune response and physiopathology caused by SARS-CoV-2, including the activation of the humoral immune response in SARS-CoV-2 infection and therefore, the synthesis of antibodies. Furthermore, we also discussed about the antibodies that can be generated in COVID-19 convalescent sera and their associated clinical studies, including a detailed characterization of a variety of human antibodies and identification of antibodies from other sources, which have powerful neutralizing capacities. Accordingly, the development of effective treatments to mitigate COVID-19 is expected. Finally, we reviewed the challenges faced in producing potential therapeutic antibodies and nanobodies by cell factories at an industrial level while ensuring their quality, efficacy, and safety.<\/jats:p>","DOI":"10.1186\/s12934-021-01576-5","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T16:13:06Z","timestamp":1619107986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment"],"prefix":"10.1186","volume":"20","author":[{"given":"Norma A.","family":"Valdez-Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Garc\u00eda-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Espitia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cobos-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Altamirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Bando-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis F.","family":"Cofas-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique W.","family":"Coronado-Aceves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo A.","family":"Gonz\u00e1lez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Hern\u00e1ndez-Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ju\u00e1rez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola A.","family":"Ortega-Portilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Restrepo-Pineda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Zelada-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7497-4452","authenticated-orcid":false,"given":"Mauricio A.","family":"Trujillo-Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"issue":"5","key":"1576_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","volume":"20","author":"E Dong","year":"2020","unstructured":"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020;20(5):533\u20134.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"1576_CR2","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S1473-3099(20)30484-9","volume":"20","author":"E Petersen","year":"2020","unstructured":"Petersen E, Koopmans M, Go U, Hamer DH, Petrosillo N, Castelli N, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis. 2020;20(9):e238\u201344.","journal-title":"Lancet Infect Dis"},{"issue":"29","key":"1576_CR3","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.1073\/pnas.0701000104","volume":"104","author":"Z Zhu","year":"2007","unstructured":"Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci USA. 2007;104(29):12123\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6510","key":"1576_CR4","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1126\/science.abc5881","volume":"369","author":"Z Lv","year":"2020","unstructured":"Lv Z, Deng YQ, Ye Q, Cao L, Sun CY, Fan C, et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science. 2020;369(6510):1505\u20139.","journal-title":"Science"},{"issue":"11","key":"1576_CR5","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/v12111226","volume":"12","author":"ZJ Cheng","year":"2020","unstructured":"Cheng ZJ, Qu HQ, Tian L, Duan Z, Hakonarson H. COVID-19: look to the future, learn from the past. Viruses. 2020;12(11):1226.","journal-title":"Viruses"},{"key":"1576_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.tim.2016.09.001","volume":"25","author":"D Forni","year":"2017","unstructured":"Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25:35\u201348.","journal-title":"Trends Microbiol"},{"issue":"1","key":"1576_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/v11010059","volume":"11","author":"Z Song","year":"2019","unstructured":"Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting Coronaviruses into the spotlight. Viruses. 2019;11(1):59.","journal-title":"Viruses"},{"issue":"6","key":"1576_CR8","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/jmv.25754","volume":"92","author":"M Kandeel","year":"2020","unstructured":"Kandeel M, Ibrahim A, Fayez M, Al-Nazawi M. From SARS and MERS CoVs to SARS-CoV-2: moving toward more biased codon usage in viral structural and nonstructural genes. J Med Virol. 2020;92(6):660\u20136.","journal-title":"J Med Virol"},{"issue":"9","key":"1576_CR9","doi-asserted-by":"publisher","first-page":"e202000786","DOI":"10.26508\/lsa.202000786","volume":"3","author":"D Bestle","year":"2020","unstructured":"Bestle D, Heindl MR, Limburg H, van Van Lam T, Pilgram O, Moulton H, et al. TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance. 2020;3(9):e202000786.","journal-title":"Life Sci Alliance"},{"issue":"2","key":"1576_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.","journal-title":"Cell"},{"issue":"13","key":"1576_CR11","doi-asserted-by":"publisher","first-page":"7001","DOI":"10.1073\/pnas.2002589117","volume":"117","author":"S Matsuyama","year":"2020","unstructured":"Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci USA. 2020;117(13):7001\u20133.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1576_CR12","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41467-020-16256-y","volume":"11","author":"C Wang","year":"2020","unstructured":"Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251.","journal-title":"Nat Commun"},{"issue":"10","key":"1576_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41594-020-0480-y","volume":"27","author":"D Zhou","year":"2020","unstructured":"Zhou D, Duyvesteyn HME, Chen CP, Huang CG, Chen TH, Shih SR, et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020;27(10):950\u20138.","journal-title":"Nat Struct Mol Biol"},{"issue":"7807","key":"1576_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","volume":"581","author":"J Shang","year":"2020","unstructured":"Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, Geng Q, Auerbach A, Li F. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581(7807):221\u20134.","journal-title":"Nature"},{"issue":"7807","key":"1576_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","volume":"581","author":"J Lan","year":"2020","unstructured":"Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215\u201320.","journal-title":"Nature"},{"issue":"6506","key":"1576_CR16","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1126\/science.abc7520","volume":"369","author":"TF Rogers","year":"2020","unstructured":"Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956\u201363.","journal-title":"Science"},{"issue":"4","key":"1576_CR17","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","volume":"183","author":"J Kreye","year":"2020","unstructured":"Kreye J, Reincke SM, Kornau HC, S\u00e1nchez-Sendin E, Corman VM, Liu H, et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model. Cell. 2020;183(4):1058-69.e19.","journal-title":"Cell"},{"issue":"6","key":"1576_CR18","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41423-020-0426-7","volume":"17","author":"X Chen","year":"2020","unstructured":"Chen X, Li R, Pan Z, Qian C, Yang Y, You R, Zhao J, Liu P, Gao L, et al. Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor. Cell Mol Immunol. 2020;17(6):647\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"1576_CR19","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Q Li","year":"2020","unstructured":"Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284-94.e9.","journal-title":"Cell"},{"issue":"1","key":"1576_CR20","doi-asserted-by":"publisher","first-page":"e00162","DOI":"10.1128\/CMR.00162-20","volume":"34","author":"JJ Malin","year":"2020","unstructured":"Malin JJ, Su\u00e1rez I, Priesner V, F\u00e4tkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2020;34(1):e00162-e220.","journal-title":"Clin Microbiol Rev"},{"issue":"19","key":"1576_CR21","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19\u2014final report. N Engl J Med. 2020;383(19):1813\u201326.","journal-title":"N Engl J Med"},{"key":"1576_CR22","doi-asserted-by":"crossref","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y. A Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569\u201378. [Erratum in: Lancet. 2020;395(10238):1694].","DOI":"10.1016\/S0140-6736(20)31022-9"},{"issue":"1","key":"1576_CR23","first-page":"1","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1\u20139.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"6","key":"1576_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1053\/j.jfas.2020.09.011","volume":"59","author":"AR Johnson","year":"2020","unstructured":"Johnson AR, McDonald AR, Malay DS. In Pursuit of a SARS-CoV-2 vaccine. J Foot Ankle Surg. 2020;59(6):1133\u20134.","journal-title":"J Foot Ankle Surg"},{"issue":"7830","key":"1576_CR25","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"F Krammer","year":"2020","unstructured":"Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516\u201327.","journal-title":"Nature"},{"issue":"7","key":"1576_CR26","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","volume":"3","author":"J ter Meulen","year":"2006","unstructured":"ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, Cox F, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med. 2006;3(7):e237.","journal-title":"PLoS Med"},{"issue":"7815","key":"1576_CR27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290\u20135.","journal-title":"Nature"},{"issue":"6491","key":"1576_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan M, Wu NC, Zhu X, Lee CD, So RTY, Lv H, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630\u20133.","journal-title":"Science"},{"issue":"1","key":"1576_CR29","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","volume":"9","author":"X Tian","year":"2020","unstructured":"Tian X, Li C, Huang A, Xia S, Lu S, Shi Z, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020;9(1):382\u20135.","journal-title":"Emerg Microbes Infect"},{"key":"1576_CR30","doi-asserted-by":"crossref","unstructured":"Huo J, Le Bas A, Ruza RR, Duyvesteyn HME, Mikolajek H, Malinauskas T, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846\u201354. [Erratum in: Nat Struct Mol Biol. 2020;27(11);1094].","DOI":"10.1038\/s41594-020-0469-6"},{"issue":"1","key":"1576_CR31","first-page":"e25","volume":"1","author":"J Maradei","year":"2020","unstructured":"Maradei J, Vanesa-Castan\u00f3 V, Luj\u00e1n-Jaureguibeh\u00e9re M. Terapia con plasma de donantes convalecientes en enfermos graves con COVID-19: un llamado a la acci\u00f3n. Revista del Hospital Dr Emilio Ferreyra. 2020;1(1):e25\u201330.","journal-title":"Revista del Hospital Dr Emilio Ferreyra"},{"issue":"1","key":"1576_CR32","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","volume":"182","author":"Y Cao","year":"2020","unstructured":"Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B Cells. Cell. 2020;182(1):73-84.e16.","journal-title":"Cell"},{"key":"1576_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/9781555817411.ch1","volume-title":"Antibodies for infectious diseases","author":"A Hey","year":"2015","unstructured":"Hey A. History and practice: antibodies in infectious diseases. In: Crowe JE, Boraschi D, Rappuoli R, editors. Antibodies for infectious diseases. Hoboken: Wiley; 2015. p. 1\u201321. https:\/\/doi.org\/10.1128\/9781555817411.ch1."},{"key":"1576_CR34","doi-asserted-by":"publisher","first-page":"20830","DOI":"10.2807\/1560-7917.ES2014.19.24.20830","volume":"19","author":"L Both","year":"2014","unstructured":"Both L, White J, Mandal S, Efstratiou A. Access to diphtheria antitoxin for therapy and diagnostics. Euro surveill. 2014;19:20830.","journal-title":"Euro surveill"},{"key":"1576_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1001\/jama.1976.03260270028022","volume":"235","author":"PA Blake","year":"1976","unstructured":"Blake PA, Feldman RA, Buchanan TM, Brooks GF, Bennett JV. Serologic therapy of tetanus in the United States, 1965\u20131971. JAMA. 1976;235:42\u20134.","journal-title":"JAMA"},{"key":"1576_CR36","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1128\/iai.64.5.1839-1841.1996","volume":"64","author":"BE Menzies","year":"1996","unstructured":"Menzies BE, Kernodle DS. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect Immun. 1996;64:1839\u201341.","journal-title":"Infect Immun"},{"key":"1576_CR37","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1128\/iai.59.6.2215-2218.1991","volume":"59","author":"DM Lyerly","year":"1991","unstructured":"Lyerly DM, Bostwick E, Binion S, Wilkins T. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun. 1991;59:2215\u20138.","journal-title":"Infect Immun"},{"key":"1576_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0022-3476(44)80101-9","volume":"24","author":"AC McGuinness","year":"1944","unstructured":"McGuinness AC, Armstrong JG, Felton HM. Hyperimmune whooping cough serum: further studies. J Pediatr. 1944;24:249\u201358.","journal-title":"J Pediatr"},{"key":"1576_CR39","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/WNL.29.6.815","volume":"29","author":"JB Bodensteiner","year":"1979","unstructured":"Bodensteiner JB, Morris H, Howell J, Schochet S. Chronic ECHO type 5 virus meningoencephalitis in X-linked hypogammaglobulinemia: treatment with immune plasma. Neurol. 1979;29:815.","journal-title":"Neurol"},{"issue":"9","key":"1576_CR40","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/00007890-199605150-00013","volume":"61","author":"RW McGory","year":"1996","unstructured":"McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61(9):1358\u201364.","journal-title":"Transplantation"},{"key":"1576_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2105\/AJPH.25.5.595","volume":"25","author":"JR Gallagher","year":"1935","unstructured":"Gallagher JR. Use of convalescent measles serum to control measles in a preparatory school. Am J Public Health Nations Health. 1935;25:595\u20138.","journal-title":"Am J Public Health Nations Health"},{"issue":"12","key":"1576_CR42","doi-asserted-by":"publisher","first-page":"926","DOI":"10.7326\/0003-4819-113-12-926","volume":"113","author":"N Frickhofen","year":"1990","unstructured":"Frickhofen N, Abkowitz JL, Safford M, Berry JM, Antunez-de-Mayolo J, Astrow A, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990;113(12):926\u201333.","journal-title":"Ann Intern Med"},{"issue":"S2","key":"1576_CR43","doi-asserted-by":"publisher","first-page":"A266","DOI":"10.1093\/infdis\/133.Supplement_2.A266","volume":"133","author":"MA Hattwick","year":"1976","unstructured":"Hattwick MA, Corey L, Creecht WB. Clinical use of human globulin immune to rabies vims. J Infect Dis. 1976;133(S2):A266\u201372.","journal-title":"J Infect Dis"},{"key":"1576_CR44","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJM199311183292102","volume":"329","author":"JR Groothuis","year":"1993","unstructured":"Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med. 1993;329:1524\u201330.","journal-title":"N Engl J Med"},{"key":"1576_CR45","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.1924.02650420009004","volume":"82","author":"A Weech","year":"1924","unstructured":"Weech A. The prophylaxis of varicella with convalescents\u2019 serum. JJAMA. 1924;82:1245\u20136.","journal-title":"JJAMA"},{"key":"1576_CR46","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nri.2017.148","volume":"18","author":"LM Walker","year":"2018","unstructured":"Walker LM, Burton DR. Passive immunotherapy of viral infections: \u201csuper-antibodies\u201d enter the fray. Nat Rev Immunol. 2018;18:297.","journal-title":"Nat Rev Immunol"},{"key":"1576_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15359","author":"F Levi-Schaffer","year":"2020","unstructured":"Levi-Schaffer F, de Marco A. COVID-19 and the revival of passive immunization: antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31. Br J pharmacol. 2020. https:\/\/doi.org\/10.1111\/bph.15359.","journal-title":"Br J pharmacol"},{"issue":"11","key":"1576_CR48","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.it.2020.09.004","volume":"41","author":"E Gavor","year":"2020","unstructured":"Gavor E, Choong YK, Er SY, Sivaraman H. Sivaraman J (2020) Structural basis of SARS-CoV-2 and SARS-CoV-antibody interactions. Trends Immunol. 2020;41(11):1006\u201322.","journal-title":"Trends Immunol"},{"issue":"9","key":"1576_CR49","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/jmv.25961","volume":"92","author":"K Rajendran","year":"2020","unstructured":"Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020;92(9):1475\u201383.","journal-title":"J Med Virol"},{"issue":"11","key":"1576_CR50","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.tips.2020.07.004","volume":"41","author":"A Renn","year":"2020","unstructured":"Renn A, Fu Y, Hu X, Hall MD, Simeonov A. Fruitful neutralizing antibody pipeline brings hope to defeat SARS-Cov-2. Trends Pharmacol Sci. 2020;41(11):815\u201329.","journal-title":"Trends Pharmacol Sci"},{"issue":"55","key":"1576_CR51","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.mcp.2020.101692","volume":"2021","author":"H Zare","year":"2021","unstructured":"Zare H, Aghamollaei H, Hosseindokht M, Heiat M, Razei A, Bakherad H. Nanobodies, the potent agents to detect and treat the Coronavirus infections: a systematic review. Mol Cell Probes. 2021;2021(55):101692.","journal-title":"Mol Cell Probes"},{"key":"1576_CR52","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btaa739","author":"MIJ Raybould","year":"2020","unstructured":"Raybould MIJ, Kovaltsuk A, Marks C, Deane CM. CoV-AbDab: the coronavirus antibody database. Bioinformatics. 2020. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa739.","journal-title":"Bioinformatics"},{"issue":"3","key":"1576_CR53","first-page":"205","volume":"3","author":"L Yang","year":"2020","unstructured":"Yang L, Liu W, Yu X, Wu M, Reichert JM, Ho M. COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antib Ther. 2020;3(3):205\u201312.","journal-title":"Antib Ther"},{"key":"1576_CR54","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ijid.2020.09.025","volume":"100","author":"JA Lednicky","year":"2020","unstructured":"Lednicky JA, Lauzardo M, Fan ZH, Jutla A, Tilly TB, Gangwar M, et al. Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. Int J Infect Dis. 2020;100:476\u201382.","journal-title":"Int J Infect Dis"},{"key":"1576_CR55","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fmed.2020.00260","volume":"7","author":"A Rodriguez-Palacios","year":"2020","unstructured":"Rodriguez-Palacios A, Cominelli F, Basson AR, Pizarro TT, Ilic S. Textile masks and surface covers-A spray simulation method and a \u201cUniversal Droplet Reduction Model\u201d against respiratory pandemics. Front Med (Lausanne). 2020;7:260.","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"1576_CR56","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1172\/JCI137244","volume":"130","author":"G Chen","year":"2020","unstructured":"Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620\u20139.","journal-title":"J Clin Invest"},{"key":"1576_CR57","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3389\/fimmu.2020.01441","volume":"11","author":"LF Garc\u00eda","year":"2020","unstructured":"Garc\u00eda LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441.","journal-title":"Front Immunol"},{"key":"1576_CR58","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1053\/j.gastro.2020.02.054","volume":"158","author":"J Gu","year":"2020","unstructured":"Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal\u2013oral transmission. Gastroenterology. 2020;158:1518\u20139.","journal-title":"Gastroenterology"},{"issue":"6499","key":"1576_CR59","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abc1669","volume":"369","author":"MM Lamers","year":"2020","unstructured":"Lamers MM, Beumer J, van der Vaart J, Knoops K, Puschhof J, Breugem TI, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369(6499):50\u20134.","journal-title":"Science"},{"issue":"6485","key":"1576_CR60","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444\u20138.","journal-title":"Science"},{"issue":"2","key":"1576_CR61","first-page":"327","volume":"34","author":"P Conti","year":"2020","unstructured":"Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327\u201331.","journal-title":"J Biol Regul Homeost Agents"},{"key":"1576_CR62","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1074\/jbc.M410592200","volume":"280","author":"L Guillot","year":"2005","unstructured":"Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem. 2005;280:5571\u201380.","journal-title":"J Biol Chem"},{"issue":"6","key":"1576_CR63","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41577-020-0331-4","volume":"20","author":"M Merad","year":"2020","unstructured":"Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol. 2020;20(6):355\u201362.","journal-title":"Nat Rev Immunol"},{"issue":"10229","key":"1576_CR64","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet"},{"key":"1576_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26232","author":"B Hu","year":"2020","unstructured":"Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.26232.","journal-title":"J Med Virol"},{"key":"1576_CR66","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-med-061813-012806","volume":"66","author":"GS Schulert","year":"2015","unstructured":"Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu Rev Med. 2015;66:145\u201359.","journal-title":"Annu Rev Med"},{"key":"1576_CR67","doi-asserted-by":"publisher","first-page":"118102","DOI":"10.1016\/j.lfs.2020.118102","volume":"257","author":"A Jafarzadeh","year":"2020","unstructured":"Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, Nemati M. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: lessons from SARS and MERS, and potential therapeutic interventions. Life Sci. 2020;257:118102.","journal-title":"Life Sci"},{"key":"1576_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41420-019-0181-7","volume":"5","author":"CS Shi","year":"2019","unstructured":"Shi CS, Nabar NR, Huang NN, Kehrl JH. SARS-Coronavirus Open Reading Frame-8b triggers intracellular stress pathways and activates NLRP3 inflammasomes. Cell Death Discov. 2019;5:101.","journal-title":"Cell Death Discov"},{"key":"1576_CR69","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3389\/fimmu.2020.01518","volume":"11","author":"TL Freeman","year":"2020","unstructured":"Freeman TL, Swartz TH. Targeting the NLRP3 Inflammasome in Severe COVID-19. Front Immunol. 2020;11:1518.","journal-title":"Front Immunol"},{"key":"1576_CR70","doi-asserted-by":"publisher","first-page":"198074","DOI":"10.1016\/j.virusres.2020.198074","volume":"286","author":"JY Li","year":"2020","unstructured":"Li JY, Liao CH, Wang Q, Tan YJ, Luo R, Qiu Y, Ge XY. The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res. 2020;286:198074.","journal-title":"Virus Res"},{"issue":"7","key":"1576_CR71","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1001\/jamainternmed.2020.0994","volume":"180","author":"C Wu","year":"2020","unstructured":"Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934\u201343.","journal-title":"JAMA Intern Med"},{"key":"1576_CR72","doi-asserted-by":"crossref","unstructured":"Barton LM, Duval EJ, Stroberg E, Ghosh S, Mukhopadhyay S. COVID-19 Autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153(6):725\u201333. [Erratum in: Am J Clin Pathol. 2020;153(6):852]","DOI":"10.1093\/ajcp\/aqaa062"},{"key":"1576_CR73","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","volume":"214","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.","journal-title":"Clin Immunol"},{"issue":"5","key":"1576_CR74","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;17(5):533\u20135.","journal-title":"Cell Mol Immunol"},{"key":"1576_CR75","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731\u201343.","journal-title":"Cell"},{"key":"1576_CR76","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.gastro.2012.10.039","volume":"144","author":"F Li","year":"2013","unstructured":"Li F, Wei H, Wei H, Gao Y, Xu L, Yin W, Sun R, Tian Z. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. Gastroenterology. 2013;144:392\u2013401.","journal-title":"Gastroenterology"},{"issue":"7","key":"1576_CR77","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41591-020-0944-y","volume":"26","author":"AJ Wilk","year":"2020","unstructured":"Wilk AJ, Rustagi A, Zhao NQ, Roque J, Mart\u00ednez-Col\u00f3n GJ, McKechnie JL, et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med. 2020;26(7):1070\u20136.","journal-title":"Nat Med"},{"key":"1576_CR78","doi-asserted-by":"publisher","DOI":"10.1101\/2020.03.29.20041962","author":"T Gao","year":"2020","unstructured":"Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.29.20041962.","journal-title":"MedRxiv"},{"issue":"6","key":"1576_CR79","doi-asserted-by":"publisher","first-page":"e20200652","DOI":"10.1084\/jem.20200652","volume":"217","author":"BJ Barnes","year":"2020","unstructured":"Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652.","journal-title":"J Exp Med"},{"issue":"4","key":"1576_CR80","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.tmrv.2019.08.004","volume":"33","author":"S Dzik","year":"2019","unstructured":"Dzik S. Complement and coagulation: cross talk through time. Transf Med Rev. 2019;33(4):199\u2013206.","journal-title":"Transf Med Rev"},{"key":"1576_CR81","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1371\/journal.pone.0000623","volume":"2","author":"A Krarup","year":"2007","unstructured":"Krarup A, Wallis R, Presanis JS, G\u00e1l P, Sim RRB. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE. 2007;2:e623.","journal-title":"PLoS ONE"},{"issue":"7","key":"1576_CR82","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","volume":"177","author":"K Ritis","year":"2006","unstructured":"Ritis K, Doumas M, Mastellos D, Micheli A, Giaglis S, Magotti P, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177(7):4794\u2013802.","journal-title":"J Immunol"},{"issue":"4","key":"1576_CR83","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1182\/blood.V68.4.875.875","volume":"68","author":"T Wiedmer","year":"1986","unstructured":"Wiedmer T, Esmon CT, Sims PJ. Complement proteins C5b\u20139 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;68(4):875\u201380.","journal-title":"Blood"},{"key":"1576_CR84","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fimmu.2019.00483","volume":"10","author":"N Rodriguez-Zhurbenko","year":"2019","unstructured":"Rodriguez-Zhurbenko N, Quach TD, Hopkins TJ, Rothstein TL, Hernandez AM. Human B-1 Cells and B-1 cell antibodies change with advancing age. Front Immunol. 2019;10:483.","journal-title":"Front Immunol"},{"issue":"15","key":"1576_CR85","doi-asserted-by":"publisher","first-page":"e140711","DOI":"10.1172\/jci.insight.140711","volume":"5","author":"A Java","year":"2020","unstructured":"Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight. 2020;5(15):e140711.","journal-title":"JCI Insight"},{"issue":"2","key":"1576_CR86","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cell.2008.02.043","volume":"133","author":"Y Imai","year":"2008","unstructured":"Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell. 2008;133(2):235\u201349.","journal-title":"Cell"},{"issue":"11","key":"1576_CR87","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1084\/jem.20150632","volume":"212","author":"R Vijay","year":"2015","unstructured":"Vijay R, Hua X, Meyerholz DK, Miki Y, Yamamoto K, Gelb M, et al. Critical role of phospholipase A2 group IID in age-related susceptibility to severe acute respiratory syndrome-CoV infection. J Exp Med. 2015;212(11):1851\u201368.","journal-title":"J Exp Med"},{"issue":"4","key":"1576_CR88","doi-asserted-by":"publisher","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","volume":"4","author":"L Liu","year":"2019","unstructured":"Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158.","journal-title":"JCI Insight"},{"issue":"41","key":"1576_CR89","doi-asserted-by":"publisher","first-page":"13958","DOI":"10.1074\/jbc.AC120.013788","volume":"295","author":"U Felgenhauer","year":"2020","unstructured":"Felgenhauer U, Schoen A, Gad HH, Hartmann R, Schaubmar AR, Failing K, et al. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem. 2020;295(41):13958\u201364.","journal-title":"J Biol Chem"},{"issue":"7","key":"1576_CR90","doi-asserted-by":"publisher","first-page":"e1008737","DOI":"10.1371\/journal.ppat.1008737","volume":"16","author":"M Sa Ribero","year":"2020","unstructured":"Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):e1008737.","journal-title":"PLoS Pathog"},{"key":"1576_CR91","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","volume":"11","author":"B Diao","year":"2020","unstructured":"Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827.","journal-title":"Front Immunol"},{"key":"1576_CR92","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3389\/fimmu.2020.01870","volume":"11","author":"M Herrmann","year":"2020","unstructured":"Herrmann M, Schulte S, Wildner NH, Wittner M, Brehm TT, Ramharter M, et al. Analysis of co-inhibitory receptor expression in COVID-19 infection compared to acute Plasmodium falciparum malaria: LAG-3 and TIM-3 Correlate with T Cell activation and course of disease. Front Immunol. 2020;11:1870.","journal-title":"Front Immunol"},{"issue":"8","key":"1576_CR93","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"1576_CR94","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989\u20131004.","journal-title":"Immunity"},{"issue":"12","key":"1576_CR95","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1590\/1806-9282.66.12.1666","volume":"66","author":"Y Kalpakci","year":"2020","unstructured":"Kalpakci Y, Hacibekiroglu T, Trak G, Karacaer C, Demirci T, Kocayigit H, et al. Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4+ CD8+ double positive T lymphocytes as a new marker. Rev Assoc Med Bras. 2020;66(12):1666\u201372.","journal-title":"Rev Assoc Med Bras"},{"issue":"9","key":"1576_CR96","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","volume":"20","author":"Z Chen","year":"2020","unstructured":"Chen Z, Wherry EJ. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020;20(9):529\u201336.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1576_CR97","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41577-020-0304-7","volume":"20","author":"C Moon","year":"2020","unstructured":"Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020;20(5):277.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"1576_CR98","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.1172\/JCI140965","volume":"130","author":"A Sattler","year":"2020","unstructured":"Sattler A, Angermair S, Stockmann H, Heim KM, Khadzhynov D, Treskatsch S, et al. SARS\u2013CoV-2\u2013specific T cell responses and correlations with COVID-19 patient predisposition. J Clin Invest. 2020;130(12):6477\u201389.","journal-title":"J Clin Invest"},{"issue":"95","key":"1576_CR99","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/ajh.25829","volume":"2020","author":"E Terpos","year":"2020","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. Am J Hematol. 2020;2020(95):834\u201347.","journal-title":"Am J Hematol"},{"issue":"1","key":"1576_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41368-020-0074-x","volume":"12","author":"H Xu","year":"2020","unstructured":"Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, et al. (2020) High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1\u20135.","journal-title":"Int J Oral Sci"},{"issue":"6","key":"1576_CR101","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-020-0901-9","volume":"26","author":"M Liao","year":"2020","unstructured":"Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842\u20134.","journal-title":"Nat Med"},{"issue":"11","key":"1576_CR102","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol. 2020;21(11):1336\u201345.","journal-title":"Nat Immunol"},{"issue":"6","key":"1576_CR103","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.xcrm.2020.100081","volume":"1","author":"J Neidleman","year":"2020","unstructured":"Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, et al. SARS-CoV-2-specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential. Cell Reports Med. 2020;1(6):100081.","journal-title":"Cell Reports Med"},{"key":"1576_CR104","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.24.111823","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang J, Chen Y, Luo B, Yuan Y, Huang F, et al. The ORF8 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-I. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.05.24.111823.","journal-title":"bioRxiv"},{"key":"1576_CR105","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/088282403763635465","volume":"16","author":"SMC Tirado","year":"2003","unstructured":"Tirado SMC, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immun. 2003;16:69\u201386.","journal-title":"Viral Immun"},{"key":"1576_CR106","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/rmv.405","volume":"13","author":"A Takada","year":"2003","unstructured":"Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003;13:387\u201398.","journal-title":"Rev Med Virol"},{"key":"1576_CR107","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.vaccine.2006.08.011","volume":"25","author":"YW Kam","year":"2007","unstructured":"Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate Fc\u03b3RII-dependent entry into B cells in vitro. Vaccine. 2007;25:729\u201340.","journal-title":"Vaccine"},{"key":"1576_CR108","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1743-422X-11-82","volume":"11","author":"MS Yip","year":"2014","unstructured":"Yip MS, Leung NH, Cheung CY, Li PH, Lee HH, Da\u00ebron M, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol J. 2014;11:82.","journal-title":"Virol J"},{"issue":"9","key":"1576_CR109","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1080\/21645515.2016.1177688","volume":"12","author":"AS Agrawal","year":"2016","unstructured":"Agrawal AS, Tao X, Algaissi A, Garron T, Narayanan K, Peng BH, et al. Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016;12(9):2351\u20136.","journal-title":"Hum Vaccin Immunother"},{"key":"1576_CR110","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1128\/jvi.64.3.1407-1409.1990","volume":"64","author":"H Vennema","year":"1990","unstructured":"Vennema H, De Groot R, Harbour D, Dalderup M, Gruffydd-Jones T, Horzinek M, Spaan W. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol. 1990;64:1407\u20139.","journal-title":"J Virol"},{"key":"1576_CR111","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1128\/JVI.75.5.2324-2330.2001","volume":"75","author":"A Takada","year":"2001","unstructured":"Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol. 2001;75:2324\u201330.","journal-title":"J Virol"},{"key":"1576_CR112","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1016\/j.vaccine.2007.12.028","volume":"26","author":"Z Beck","year":"2008","unstructured":"Beck Z, Proh\u00e1szka Z, F\u00fcst G. Traitors of the immune system\u2014enhancing antibodies in HIV infection: their possible implication in HIV vaccine development. Vaccine. 2008;26:3078\u201385.","journal-title":"Vaccine"},{"key":"1576_CR113","first-page":"w20249","volume":"150","author":"F Negro","year":"2020","unstructured":"Negro F. Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis? Swiss Med Wkly. 2020;150:w20249.","journal-title":"Swiss Med Wkly"},{"key":"1576_CR114","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.08.20209114","author":"F Wu","year":"2020","unstructured":"Wu F, Yan R, Liu M, Liu Z, Wang Y, Luan D, et al. Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis. MedRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.10.08.20209114.","journal-title":"MedRxiv."},{"key":"1576_CR115","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/ni0708-705","volume":"9","author":"SH Kaufmann","year":"2008","unstructured":"Kaufmann SH. Immunology\u2019s foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. Nature Immunol. 2008;9:705\u201312.","journal-title":"Nature Immunol"},{"key":"1576_CR116","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1055\/s-0029-1206682","volume":"17","author":"P Ehrlich","year":"1981","unstructured":"Ehrlich P. Experimentelle untersuchungen \u00fcber immunit\u00e4t. I. Ueber ricin. DMW-Deutsche Medizinische Wochenschrift. 1981;17:976\u20139.","journal-title":"DMW-Deutsche Medizinische Wochenschrift"},{"key":"1576_CR117","first-page":"1","volume":"16","author":"Y Muhammed","year":"2020","unstructured":"Muhammed Y. The best IgG subclass for the development of therapeutic monoclonal antibody drugs and their commercial production: a review. Immunome Res. 2020;16:1\u201312.","journal-title":"Immunome Res"},{"issue":"1","key":"1576_CR118","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","volume":"109","author":"Y Le Basle","year":"2020","unstructured":"Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020;109(1):169\u201390.","journal-title":"J Pharm Sci"},{"key":"1576_CR119","unstructured":"Harris R. Heterogeneity of recombinant antibodies: linking structure to function. Mire-Sluis AR, editor. State of the art analytical methods for the characterization of biological. Products and assessment of comparability. (Dev BioI, Basel, Karger, 200S, vol 122, pp 117\u2013127; 2005)."},{"issue":"3","key":"1576_CR120","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/cei.13253","volume":"195","author":"S Arakawa","year":"2019","unstructured":"Arakawa S, Suzukawa M, Watanabe K, Kobayashi K, Matsui H, Nagai H, et al. Secretory immunoglobulin A induces human lung fibroblasts to produce inflammatory cytokines and undergo activation. Clin Exp Immunol. 2019;195(3):287\u2013301.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"1576_CR121","doi-asserted-by":"publisher","first-page":"2001526","DOI":"10.1183\/13993003.01526-2020","volume":"56","author":"HQ Yu","year":"2020","unstructured":"Yu HQ, Sun BQ, Fang ZF, Zhao JC, Liu XY, Li YM, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020;56(2):2001526.","journal-title":"Eur Respir J"},{"issue":"7","key":"1576_CR122","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/eji.201646547","volume":"48","author":"C Gutzeit","year":"2018","unstructured":"Gutzeit C, Chen K, Cerutti A. The enigmatic function of IgD: some answers at last. Eur J Immunol. 2018;48(7):1101\u201313.","journal-title":"Eur J Immunol"},{"issue":"8","key":"1576_CR123","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1748","volume":"10","author":"K Chen","year":"2009","unstructured":"Chen K, Xu W, Wilson M, He B, Miller NW, Bengt\u00e9n E, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol. 2009;10(8):889\u201398.","journal-title":"Nat Immunol"},{"key":"1576_CR124","doi-asserted-by":"publisher","DOI":"10.1128\/9781555816148","volume-title":"Immunology, infection, and immunity","author":"GB Pier","year":"2004","unstructured":"Pier GB, Lyczak JB, Wetzler LM. Immunology, infection, and immunity. Washington: ASM press; 2004."},{"key":"1576_CR125","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"1576_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2776(01)79001-3","volume":"79","author":"RM Zinkernagel","year":"2001","unstructured":"Zinkernagel RM, LaMarre A, Ciurea A, Hunziker L, Ochsenbein AF, McCoy KD, et al. Neutralizing antiviral antibody responses. Adv Immunol. 2001;79:1\u201353.","journal-title":"Adv Immunol"},{"issue":"15","key":"1576_CR127","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/cid\/ciaa310","volume":"71","author":"L Guo","year":"2020","unstructured":"Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778\u201385.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"1576_CR128","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Liu BZ, Deng HJ, Wu CG, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845\u20138.","journal-title":"Nat Med"},{"key":"1576_CR129","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.cca.2020.04.026","volume":"507","author":"A Padoan","year":"2020","unstructured":"Padoan A, Sciacovelli L, Basso D, Negrini D, Zuin S, Cosma C, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta. 2020;507:164\u20136.","journal-title":"Clin Chim Acta"},{"issue":"9","key":"1576_CR130","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1007\/s00134-020-06157-5","volume":"46","author":"S Fourati","year":"2020","unstructured":"Fourati S, Hue S, Pawlotsky JM, Mekontso-Dessap A, de Prost N. SARS-CoV-2 viral loads and serum IgA\/IgG immune responses in critically ill COVID-19 patients. Intensive Care Med. 2020;46(9):1781\u20133.","journal-title":"Intensive Care Med"},{"key":"1576_CR131","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18:46.","journal-title":"Nat Rev Immunol"},{"key":"1576_CR132","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.16.20196154","author":"H Natarajan","year":"2020","unstructured":"Natarajan H, Crowley AR, Butler SE, Xu S, Weiner JA, Bloch EM, et al. SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.09.16.20196154.","journal-title":"medRxiv"},{"issue":"2 Suppl 2","key":"1576_CR133","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder Jr","year":"2010","unstructured":"Schroeder HW Jr, Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41-52.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1576_CR134","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.immuni.2020.04.023","volume":"52","author":"L Ni","year":"2020","unstructured":"Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971-7.e3.","journal-title":"Immunity"},{"issue":"7819","key":"1576_CR135","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115\u20139.","journal-title":"Nature"},{"issue":"6504","key":"1576_CR136","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer PJM, Caniels TG, van der Straten K, Snitselaar JL, Aldon Y, Bangaru S, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643\u201350.","journal-title":"Science"},{"issue":"4","key":"1576_CR137","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2020.06.044","volume":"182","author":"C Kreer","year":"2020","unstructured":"Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, et al. Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. Cell. 2020;182(4):843-54.e12.","journal-title":"Cell"},{"issue":"4","key":"1576_CR138","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.cell.2020.06.025","volume":"182","author":"CO Barnes","year":"2020","unstructured":"Barnes CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell. 2020;182(4):828-42.e16.","journal-title":"Cell"},{"key":"1576_CR139","first-page":"1","volume":"27","author":"H Shu","year":"2020","unstructured":"Shu H, Wang S, Ruan S, Wang Y, Zhang J, Yuan Y, et al. Dynamic changes of antibodies to SARS-CoV-2 in COVID-19 patients at early stage of outbreak. Virol Sin. 2020;27:1\u20138.","journal-title":"Virol Sin"},{"key":"1576_CR140","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.09.195263","author":"S Du","year":"2020","unstructured":"Du S, Cao Y, Zhu Q, Wang G, Du X, He R, et al. Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.07.09.195263.","journal-title":"bioRxiv"},{"issue":"6504","key":"1576_CR141","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1126\/science.abc6952","volume":"369","author":"X Chi","year":"2020","unstructured":"Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369(6504):650\u20135.","journal-title":"Science"},{"issue":"7821","key":"1576_CR142","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584(7821):437\u201342.","journal-title":"Nature"},{"issue":"9","key":"1576_CR143","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41591-020-0998-x","volume":"26","author":"SJ Zost","year":"2020","unstructured":"Zost SJ, Gilchuk P, Chen RE, Case JB, Reidy JX, Trivette A, et al. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nat Med. 2020;26(9):1422\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"1576_CR144","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.immuni.2020.06.001","volume":"53","author":"E Seydoux","year":"2020","unstructured":"Seydoux E, Homad LJ, MacCamy AJ, Parks KR, Hurlburt NK, Jennewein MF, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 2020;53(1):98-105.e5.","journal-title":"Immunity"},{"issue":"6506","key":"1576_CR145","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010\u20134.","journal-title":"Science"},{"issue":"6496","key":"1576_CR146","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science. 2020;368(6496):1274\u20138.","journal-title":"Science"},{"issue":"16","key":"1576_CR147","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582\u20139.","journal-title":"JAMA"},{"issue":"1","key":"1576_CR148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","volume":"222","author":"QL Zeng","year":"2020","unstructured":"Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38\u201343.","journal-title":"J Infect Dis"},{"issue":"1","key":"1576_CR149","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.chest.2020.03.039","volume":"158","author":"B Zhang","year":"2020","unstructured":"Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest. 2020;158(1):e9\u201313.","journal-title":"Chest"},{"issue":"10","key":"1576_CR150","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/jmv.25882","volume":"92","author":"M Ye","year":"2020","unstructured":"Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T. Treatment with convalescent plasma for COVID-19 patients in Wuhan. China J Med Virol. 2020;92(10):1890\u2013901.","journal-title":"China J Med Virol"},{"issue":"14","key":"1576_CR151","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.3346\/jkms.2020.35.e149","volume":"35","author":"JY Ahn","year":"2020","unstructured":"Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14):e149.","journal-title":"J Korean Med Sci"},{"issue":"17","key":"1576_CR152","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1073\/pnas.2004168117","volume":"117","author":"K Duan","year":"2020","unstructured":"Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1576_CR153","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1001\/jama.2020.10044","volume":"324","author":"L Li","year":"2020","unstructured":"Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460\u201370.","journal-title":"JAMA"},{"key":"1576_CR154","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.08.138990","author":"E Salazar","year":"2020","unstructured":"Salazar E, Kuchipudi SV, Christensen PA, Eagar TN, Yi X, Zhao P, et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. biorxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.08.138990.","journal-title":"biorxiv"},{"key":"1576_CR155","doi-asserted-by":"crossref","unstructured":"Perotti C, Baldanti F, Bruno R, del Fante C, Seminari E, Casari S, et al. Covid-19 plasma task force, Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter trial. Haematologica. 2020; 23:haematol.2020.261784.","DOI":"10.1101\/2020.05.26.20113373"},{"key":"1576_CR156","first-page":"1","volume":"20","author":"D Ibrahim","year":"2020","unstructured":"Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. Infect Dis Ther. 2020;20:1\u201314.","journal-title":"Infect Dis Ther"},{"issue":"5","key":"1576_CR157","doi-asserted-by":"publisher","first-page":"102875","DOI":"10.1016\/j.transci.2020.102875","volume":"59","author":"H Abolghasemi","year":"2020","unstructured":"Abolghasemi H, Eshghi P, Cheraghali AM, Imani Fooladi AA, Bolouki Moghaddam F, Imanizadeh S, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: results of a multicenter clinical study. Transf Apher Sci. 2020;59(5):102875.","journal-title":"Transf Apher Sci"},{"issue":"6","key":"1576_CR158","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood.2020006964","volume":"136","author":"L Hegerova","year":"2020","unstructured":"Hegerova L, Gooley TA, Sweerus KA, Maree C, Bailey N, Bailey M, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136(6):759\u201362.","journal-title":"Blood"},{"issue":"11","key":"1576_CR159","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","volume":"26","author":"STH Liu","year":"2020","unstructured":"Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020;26(11):1708\u201313.","journal-title":"Nat Med"},{"issue":"6","key":"1576_CR160","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1182\/blood.2020007079","volume":"136","author":"X Xia","year":"2020","unstructured":"Xia X, Li K, Wu L, Wang Z, Zhu M, Huang B, et al. Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion. Blood. 2020;136(6):755\u20139.","journal-title":"Blood"},{"issue":"9","key":"1576_CR161","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1172\/JCI140200","volume":"130","author":"MJ Joyner","year":"2020","unstructured":"Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020;130(9):4791\u20137.","journal-title":"J Clin Invest"},{"issue":"1","key":"1576_CR162","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41231-020-00068-9","volume":"5","author":"WR Hartman","year":"2020","unstructured":"Hartman WR, Hess AS, Connor JP. Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest. Transl Med Commun. 2020;5(1):17.","journal-title":"Transl Med Commun"},{"issue":"3","key":"1576_CR163","doi-asserted-by":"publisher","first-page":"102790","DOI":"10.1016\/j.transci.2020.102790","volume":"59","author":"BL Brown","year":"2020","unstructured":"Brown BL, McCullough J. Treatment for emerging viruses: convalescent plasma and COVID-19. Transf Apher Sci. 2020;59(3):102790.","journal-title":"Transf Apher Sci"},{"issue":"8","key":"1576_CR164","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599\u2013609.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1576_CR165","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44\u20136.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"1576_CR166","doi-asserted-by":"publisher","first-page":"e00072","DOI":"10.1128\/CMR.00072-20","volume":"33","author":"D Focosi","year":"2020","unstructured":"Focosi D, Anderson AO, Tang JW, Tuccori M. Convalescent plasma therapy for COVID-19: state of the art. Clin Microbiol Rev. 2020;33(4):e00072-e120.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1576_CR167","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","volume":"24","author":"AC Cunningham","year":"2020","unstructured":"Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24(1):91.","journal-title":"Crit Care"},{"issue":"9","key":"1576_CR168","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.3201\/eid2209.151164","volume":"22","author":"YM Arabi","year":"2016","unstructured":"Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV Infection. Saudi Arabia Emerg Infect Dis. 2016;22(9):1554\u201361.","journal-title":"Saudi Arabia Emerg Infect Dis"},{"issue":"11","key":"1576_CR169","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1172\/JCI142004","volume":"130","author":"SL Klein","year":"2020","unstructured":"Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141\u201350.","journal-title":"J Clin Invest"},{"key":"1576_CR170","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12940","author":"M Franchini","year":"2020","unstructured":"Franchini M, Marano G, Velati C, Pati I, Pupella S, Liumbruno GM. Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang. 2020. https:\/\/doi.org\/10.1111\/vox.12940.","journal-title":"Vox Sang"},{"issue":"1","key":"1576_CR171","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80\u201390.","journal-title":"J Infect Dis"},{"issue":"5","key":"1576_CR172","doi-asserted-by":"publisher","first-page":"102936","DOI":"10.1016\/j.transci.2020.102936","volume":"59","author":"T Lung","year":"2020","unstructured":"Lung T, Kazatchkine MD, Risch L, Risch M, Nydegger UE. A consideration of convalescent plasma and plasma derivatives in the care of Severely-ill patients with COVID-19. Transfus Apher Sci. 2020;59(5):102936.","journal-title":"Transfus Apher Sci"},{"key":"1576_CR173","first-page":"045","volume":"7","author":"N Singh","year":"2020","unstructured":"Singh N, Pandey A. Blood plasma from survivors of COVID-19: a novel and next frontier approach to fight against pandemic coronavirus. Int J Immunol Immunother. 2020;7:045.","journal-title":"Int J Immunol Immunother"},{"issue":"1","key":"1576_CR174","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/infdis\/jiaa673","volume":"223","author":"WT Lee","year":"2021","unstructured":"Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, et al. Neutralizing antibody responses in COVID-19 convalescent sera. J Infect Dis. 2021;223(1):47\u201355.","journal-title":"J Infect Dis"},{"key":"1576_CR175","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa803","author":"RC Girardin","year":"2021","unstructured":"Girardin RC, Dupuis AP, Payne AF, Sullivan TJ, Strauss D, Parker MM, McDonough KA. Temporal analysis of serial donations reveals decrease in neutralizing capacity and justifies revised qualifying criteria for COVID-19 convalescent plasma. J Inf Dis. 2021. https:\/\/doi.org\/10.1093\/infdis\/jiaa803.","journal-title":"J Inf Dis."},{"issue":"1","key":"1576_CR176","first-page":"10","volume":"38","author":"B Shanmugaraj","year":"2020","unstructured":"Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10\u20138.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"3","key":"1576_CR177","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","volume":"182","author":"AO Hassan","year":"2020","unstructured":"Hassan AO, Case JB, Winkler ES, Thackray LB, Kafai NM, Bailey AL, et al. A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies. Cell. 2020;182(3):744-753.e4.","journal-title":"Cell"},{"issue":"4","key":"1576_CR178","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 Spike Receptor-Binding Domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024-1042.e21.","journal-title":"Cell"},{"key":"1576_CR179","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","volume":"17","author":"CJ Bracken","year":"2021","unstructured":"Bracken CJ, Lim SA, Solomon P, Rettko NJ, Nguyen DP, Zha BS, et al. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat Chem Biol. 2021;17:113\u201321.","journal-title":"Nat Chem Biol"},{"key":"1576_CR180","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.13.381533","author":"SA Clark","year":"2020","unstructured":"Clark SA, Clark LE, Pan J, Coscia A, McKay LGA, Shankar S, et al. Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.11.13.381533.","journal-title":"bioRxiv"},{"issue":"29","key":"1576_CR181","doi-asserted-by":"publisher","first-page":"11570","DOI":"10.1073\/pnas.1204514109","volume":"109","author":"B El Debs","year":"2012","unstructured":"El Debs B, Utharala R, Balyasnikova IV, Griffiths AD, Merten CA. Functional single-cell hybridoma screening using droplet-based microfluidics. Proc Natl Acad Sci USA. 2012;109(29):11570\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1576_CR182","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/22221751.2019.1614885","volume":"8","author":"X Niu","year":"2019","unstructured":"Niu X, Zhao L, Qu L, Yao Z, Zhang F, Yan Q. Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model. Emerg Microbes Infect. 2019;8(1):749\u201359.","journal-title":"Emerg Microbes Infect"},{"issue":"5950","key":"1576_CR183","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.1178746","volume":"326","author":"LM Walker","year":"2009","unstructured":"Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285\u20139.","journal-title":"Science"},{"issue":"10","key":"1576_CR184","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41594-020-0483-8","volume":"27","author":"M McCallum","year":"2020","unstructured":"McCallum M, Walls AC, Bowen JE, Corti D, Veesler D. Structure-guided covalent stabilization of coronavirus spike glycoprotein trimers in the closed conformation. Nat Struct Mol Biol. 2020;27(10):942\u20139.","journal-title":"Nat Struct Mol Biol"},{"key":"1576_CR185","doi-asserted-by":"publisher","first-page":"576622","DOI":"10.3389\/fimmu.2020.576622","volume":"11","author":"L Duan","year":"2020","unstructured":"Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens. Front Immunol. 2020;11:576622.","journal-title":"Front Immunol"},{"key":"1576_CR186","doi-asserted-by":"publisher","first-page":"118056","DOI":"10.1016\/j.lfs.2020.118056","volume":"257","author":"A Sternberg","year":"2020","unstructured":"Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: targets for vaccination. Life Sci. 2020;257:118056.","journal-title":"Life Sci"},{"key":"1576_CR187","doi-asserted-by":"crossref","unstructured":"Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020;30(7):1346\u20131351.e2. [Erratum in: Curr. Biol. 2020;30(8):1578].","DOI":"10.1016\/j.cub.2020.03.022"},{"issue":"6483","key":"1576_CR188","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260\u20133.","journal-title":"Science"},{"key":"1576_CR189","doi-asserted-by":"publisher","first-page":"eabe5575","DOI":"10.1126\/sciadv.abe5575","volume":"7","author":"C Xu","year":"2020","unstructured":"Xu C, Wang Y, Liu C, Zhang C, Han W, Hong X, et al. Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci Adv. 2020;7:eabe5575.","journal-title":"Sci Adv"},{"issue":"10","key":"1576_CR190","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","volume":"27","author":"R Henderson","year":"2020","unstructured":"Henderson R, Edwards RJ, Mansouri K, Janowska K, Stalls V, Gobeil SMC, et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat Struct Mol Biol. 2020;27(10):925\u201333.","journal-title":"Nat Struct Mol Biol"},{"issue":"16","key":"1576_CR191","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","volume":"113","author":"P Bruhns","year":"2009","unstructured":"Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Da\u00ebron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009;113(16):3716\u201325.","journal-title":"Blood"},{"key":"1576_CR192","doi-asserted-by":"crossref","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2);281\u2013292.e6. [Erratum in: Cell 2020;183(6):1735]","DOI":"10.1016\/j.cell.2020.02.058"},{"issue":"1","key":"1576_CR193","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-020-00318-0","volume":"5","author":"F Yu","year":"2020","unstructured":"Yu F, Xiang R, Deng X, Wang L, Yu Z, Tian S, et al. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2. Signal Transduct Target Ther. 2020;5(1):212.","journal-title":"Signal Transduct Target Ther"},{"issue":"7839","key":"1576_CR194","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682\u20137.","journal-title":"Nature"},{"issue":"10224","key":"1576_CR195","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374.","journal-title":"Lancet"},{"key":"1576_CR196","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.15.341636","author":"E Rujas","year":"2020","unstructured":"Rujas E, Kucharska I, Tan YZ, Benlekbir S, Cui H, Zhao T, et al. Multivalency transforms SARS-CoV-2 antibodies into broad and ultrapotent neutralizers. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.10.15.341636.","journal-title":"bioRxiv"},{"issue":"23","key":"1576_CR197","doi-asserted-by":"publisher","first-page":"15829","DOI":"10.1074\/jbc.M600697200","volume":"281","author":"P Prabakaran","year":"2006","unstructured":"Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem. 2006;281(23):15829\u201336.","journal-title":"J Biol Chem"},{"issue":"45","key":"1576_CR198","doi-asserted-by":"publisher","first-page":"34610","DOI":"10.1074\/jbc.M603275200","volume":"281","author":"WC Hwang","year":"2006","unstructured":"Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, et al. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem. 2006;281(45):34610\u20136.","journal-title":"J Biol Chem"},{"key":"1576_CR199","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.30.178897","author":"P Acharya","year":"2020","unstructured":"Acharya P, Williams W, Henderson R, Janowska K, Manne K, Parks R, et al. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.30.178897.","journal-title":"bioRxiv"},{"key":"1576_CR200","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.30.318972","author":"BE Jones","year":"2020","unstructured":"Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.09.30.318972.","journal-title":"bioRxiv"},{"issue":"6506","key":"1576_CR201","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1126\/science.abd0831","volume":"369","author":"A Baum","year":"2020","unstructured":"Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014\u20138.","journal-title":"Science"},{"issue":"3","key":"1576_CR202","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa2029849","volume":"384","author":"P Chen","year":"2021","unstructured":"Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384(3):229\u201337.","journal-title":"N Engl J Med"},{"issue":"10","key":"1576_CR203","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMoa2033130","volume":"384","author":"JD Lundgren","year":"2021","unstructured":"ACTIV-3\/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, et al. A neutralizing monoclonal antibody for hospitalized patients with Covid-19. N Engl J Med. 2021;384(10):905\u201314.","journal-title":"N Engl J Med"},{"issue":"7819","key":"1576_CR204","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi R, Shan C, Duan X, Chen Z, Liu P, Song J, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120\u20134.","journal-title":"Nature"},{"issue":"7821","key":"1576_CR205","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","volume":"584","author":"L Liu","year":"2020","unstructured":"Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450\u20136.","journal-title":"Nature"},{"key":"1576_CR206","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108950","author":"M Rapp","year":"2021","unstructured":"Rapp M, Guo Y, Reddem ER, Liu L, Wang P, Yu J, et al. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Rep. 2021. https:\/\/doi.org\/10.1016\/j.celrep.2021.108950.","journal-title":"Cell Rep"},{"key":"1576_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.03.005","author":"G Cerutti","year":"2021","unstructured":"Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021. https:\/\/doi.org\/10.1016\/j.chom.2021.03.005.","journal-title":"Cell Host Microbe"},{"issue":"7821","key":"1576_CR208","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443\u20139.","journal-title":"Nature"},{"issue":"2","key":"1576_CR209","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.09.007","volume":"183","author":"W Li","year":"2020","unstructured":"Li W, Sch\u00e4fer A, Kulkarni SS, Liu X, Martinez DR, Chen C, et al. High potency of a bivalent human VH domain in SARS-CoV-2 animal models. Cell. 2020;183(2):429-441.e16.","journal-title":"Cell"},{"issue":"1","key":"1576_CR210","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41467-020-20465-w","volume":"12","author":"C Zhang","year":"2021","unstructured":"Zhang C, Wang Y, Zhu Y, Liu C, Gu C, Xu S, et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun. 2021;12(1):264.","journal-title":"Nat Commun"},{"issue":"4","key":"1576_CR211","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","volume":"182","author":"B Korber","year":"2020","unstructured":"Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812-827.e19.","journal-title":"Cell"},{"key":"1576_CR212","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.03.409318","author":"F Bertoglio","year":"2020","unstructured":"Bertoglio F, F\u00fchner V, Ruschig M, Heine PA, Rand U, Kl\u00fcnemann T, et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.12.03.409318.","journal-title":"bioRxiv"},{"key":"1576_CR213","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41422-020-00444-y","volume":"31","author":"H Yao","year":"2021","unstructured":"Yao H, Sun Y, Deng YQ, Wang N, Tan Y, Zhang NN, et al. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. Cell Res. 2021;31:25\u201336.","journal-title":"Cell Res"},{"issue":"3","key":"1576_CR214","doi-asserted-by":"publisher","first-page":"107918","DOI":"10.1016\/j.celrep.2020.107918","volume":"32","author":"J Wan","year":"2020","unstructured":"Wan J, Xing S, Ding L, Wang Y, Gu C, Wu Y, et al. Human-IgG-neutralizing monoclonal antibodies block the SARS-CoV-2 infection. Cell Rep. 2020;32(3):107918.","journal-title":"Cell Rep"},{"issue":"3","key":"1576_CR215","first-page":"211","volume":"10","author":"Z Shervani","year":"2020","unstructured":"Shervani Z, Khan I, Khan T, Qazi UY. World\u2019s fastest supercomputer picks COVID-19 drug. Adv Infect Dis. 2020;10(3):211.","journal-title":"Adv Infect Dis"},{"issue":"1","key":"1576_CR216","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/imr.12482","volume":"275","author":"S Bournazos","year":"2017","unstructured":"Bournazos S, Ravetch JV. Anti-retroviral antibody Fc\u03b3R-mediated effector functions. Immunol Rev. 2017;275(1):285\u201395.","journal-title":"Immunol Rev"},{"issue":"9","key":"1576_CR217","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591\u2013604.","journal-title":"J Biol Chem"},{"issue":"1","key":"1576_CR218","doi-asserted-by":"publisher","first-page":"1690959","DOI":"10.1080\/19420862.2019.1690959","volume":"12","author":"B Wang","year":"2020","unstructured":"Wang B, Yang C, Jin X, Du Q, Wu H, Dall\u2019Acqua W, Mazor Y. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen. MAbs. 2020;12(1):1690959.","journal-title":"MAbs"},{"issue":"2","key":"1576_CR219","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/19420862.2017.1405203","volume":"10","author":"O Popp","year":"2018","unstructured":"Popp O, Moser S, Zielonka J, R\u00fcger P, Hansen S, Pl\u00f6ttner O. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function. MAbs. 2018;10(2):290\u2013303.","journal-title":"MAbs"},{"key":"1576_CR220","first-page":"301","volume":"386","author":"F Krammer","year":"2015","unstructured":"Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol. 2015;386:301\u201321.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"30","key":"1576_CR221","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, Oconnell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733\u201340.","journal-title":"J Biol Chem"},{"key":"1576_CR222","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466\u201373.","journal-title":"J Biol Chem"},{"issue":"6519","key":"1576_CR223","doi-asserted-by":"publisher","first-page":"0950","DOI":"10.1126\/science.abe3354","volume":"370","author":"MA Tortorici","year":"2020","unstructured":"Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, et al. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science. 2020;370(6519):0950\u20137.","journal-title":"Science"},{"issue":"5517","key":"1576_CR224","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495\u20137.","journal-title":"Nature"},{"issue":"1","key":"1576_CR225","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imr.12395","volume":"270","author":"MJ Kwakkenbos","year":"2016","unstructured":"Kwakkenbos MJ, van Helden PM, Beaumont T, Spits H. Stable long-term cultures of self-renewing B cells and their applications. Immunol Rev. 2016;270(1):65\u201377.","journal-title":"Immunol Rev"},{"issue":"1","key":"1576_CR226","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41598-020-58571-w","volume":"10","author":"M Listek","year":"2020","unstructured":"Listek M, H\u00f6now A, Gossen M, Hanack K. A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line. Sci Rep. 2020;10(1):1664.","journal-title":"Sci Rep"},{"issue":"1","key":"1576_CR227","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1038\/s41467-020-18058-8","volume":"11","author":"M Ejemel","year":"2020","unstructured":"Ejemel M, Li Q, Hou S, Schiller ZA, Tree JA, Wallace A, et al. A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction. Nat Commun. 2020;11(1):4198.","journal-title":"Nat Commun"},{"issue":"23","key":"1576_CR228","doi-asserted-by":"publisher","first-page":"9167","DOI":"10.3390\/ijms21239167","volume":"21","author":"NV Antipova","year":"2020","unstructured":"Antipova NV, Larionova TD, Siniavin AE, Nikiforova MA, Gushchin VA, Babichenko II, et al. Establishment of murine hybridoma cells producing antibodies against spike protein of SARS-CoV-2. Int J Mol Sci. 2020;21(23):9167.","journal-title":"Int J Mol Sci"},{"key":"1576_CR229","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jbc.2021.100346","volume":"296","author":"Y Guo","year":"2021","unstructured":"Guo Y, Kawaguchi A, Takeshita M, Sekiya T, Hirohama M, et al. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection. J Biol Chem. 2021;296:100346.","journal-title":"J Biol Chem"},{"key":"1576_CR230","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.13.338095","author":"AP Chapman","year":"2020","unstructured":"Chapman AP, Tang X, Lee JR, Chida A, Mercer K, Wharton RE, et al. Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.10.13.338095.","journal-title":"bioRxiv"},{"key":"1576_CR231","doi-asserted-by":"crossref","unstructured":"Menachery VD, Yount BL Jr, Debbink K, Agnihothram S, Gralinski LE, Plante JA, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21(12):1508\u201313. [Erratum in: Nat Med 2016;22(4):446].","DOI":"10.1038\/nm.3985"},{"issue":"10","key":"1576_CR232","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.it.2020.08.002","volume":"41","author":"Z Ma","year":"2020","unstructured":"Ma Z, Li P, Ikram A, Pan Q. Does cross-neutralization of SARS-CoV-2 only relate to high pathogenic coronaviruses? Trends Immunol. 2020;41(10):851\u20133.","journal-title":"Trends Immunol"},{"issue":"6428","key":"1576_CR233","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","volume":"363","author":"C Hamers-Casterman","year":"1993","unstructured":"Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363(6428):446\u20138.","journal-title":"Nature"},{"issue":"4","key":"1576_CR234","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0161-5890(01)00057-8","volume":"38","author":"SD Nuttall","year":"2001","unstructured":"Nuttall SD, Krishnan UV, Hattarki M, De Gori R, Irving RA, Hudson PJ. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol. 2001;38(4):313\u201326.","journal-title":"Mol Immunol"},{"issue":"11","key":"1576_CR235","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/nprot.2007.448","volume":"2","author":"CM Lee","year":"2007","unstructured":"Lee CM, Iorno N, Sierro F, Christ D. Selection of human antibody fragments by phage display. Nat Protoc. 2007;2(11):3001\u20138.","journal-title":"Nat Protoc"},{"issue":"1","key":"1576_CR236","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/antib9010006","volume":"9","author":"P Chames","year":"2020","unstructured":"Chames P, Rothbauer U. Special Issue: Nanobody. Antibodies (Basel). 2020;9(1):6.","journal-title":"Antibodies (Basel)"},{"issue":"7","key":"1576_CR237","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/d41573-019-00104-w","volume":"18","author":"C Morrison","year":"2019","unstructured":"Morrison C. Nanobody approval gives domain antibodies a boost. Nat Rev Drug Discov. 2019;18(7):485\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"1576_CR238","doi-asserted-by":"crossref","unstructured":"Wrapp D, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. Structural basis for potent neutralization of Betacoronaviruses by single-domain camelid antibodies. Cell 2020;181(5):1004\u20131015.e15. [Erratum in: Cell 2020;181(6):1436\u20131441].","DOI":"10.1016\/j.cell.2020.04.031"},{"issue":"1","key":"1576_CR239","doi-asserted-by":"publisher","first-page":"5838","DOI":"10.1038\/s41467-020-19684-y","volume":"11","author":"R Boudewijns","year":"2020","unstructured":"Boudewijns R, Thibaut HJ, Kaptein SJF, Li R, Vergote V, Seldeslachts L, Van Weyenbergh J, et al. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters. Nat Commun. 2020;11(1):5838.","journal-title":"Nat Commun"},{"issue":"1","key":"1576_CR240","doi-asserted-by":"publisher","first-page":"22370","DOI":"10.1038\/s41598-020-79036-0","volume":"10","author":"TJ Esparza","year":"2020","unstructured":"Esparza TJ, Martin NP, Anderson GP, Goldman ER, Brody DL. High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Sci Rep. 2020;10(1):22370.","journal-title":"Sci Rep"},{"key":"1576_CR241","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1038\/s41598-021-82833-w","volume":"11","author":"G Valenzuela Nieto","year":"2021","unstructured":"Valenzuela Nieto G, Jara R, Watterson D, Modhiran N, Amarilla AA, Himelreichs J, et al. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody. Sci Rep. 2021;11:3318.","journal-title":"Sci Rep"},{"issue":"1","key":"1576_CR242","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1038\/s41467-020-18174-5","volume":"11","author":"L Hanke","year":"2020","unstructured":"Hanke L, Vidakovics Perez L, Sheward DJ, Das H, Schulte T, Moliner-Morro A, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun. 2020;11(1):4420.","journal-title":"Nat Commun"},{"issue":"12","key":"1576_CR243","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.3390\/biom10121661","volume":"10","author":"A Moliner-Morro","year":"2020","unstructured":"Moliner-Morro A, Sheward D, Karl V, Perez Vidakovics L, Murrell B, McInerney GM, Hanke L. Picomolar SARS-CoV-2 neutralization using multi-arm PEG nanobody constructs. Biomolecules. 2020;10(12):1661.","journal-title":"Biomolecules"},{"key":"1576_CR244","doi-asserted-by":"publisher","DOI":"10.1101\/2020.09.22.308338","author":"TR Wagner","year":"2020","unstructured":"Wagner TR, Kaiser PD, Gramlich M, Becker M, Traenkle B, Junker D, et al. NeutrobodyPlex-Nanobodies to monitor a SARS-CoV-2 neutralizing immune response. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.09.22.308338.","journal-title":"bioRxiv"},{"issue":"6523","key":"1576_CR245","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1126\/science.abe4747","volume":"370","author":"Y Xiang","year":"2020","unstructured":"Xiang Y, Nambulli S, Xiao Z, Liu H, Sang Z, Duprex WP, et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479\u201384.","journal-title":"Science"},{"key":"1576_CR246","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/mco2.60","volume":"2","author":"J Gai","year":"2021","unstructured":"Gai J, Ma L, Li G, Zhu M, Qiao P, Li X, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm. 2021;2:101\u201313.","journal-title":"MedComm"},{"issue":"5","key":"1576_CR247","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41596-020-0304-x","volume":"15","author":"I Zimmermann","year":"2020","unstructured":"Zimmermann I, Egloff P, Hutter CAJ, Kuhn BT, Br\u00e4uer P, Newstead S, et al. Seeger, generation of synthetic nanobodies against delicate proteins. Nat Protoc. 2020;15(5):1707\u201341.","journal-title":"Nat Protoc"},{"key":"1576_CR248","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.16.045419","author":"JD Walter","year":"2020","unstructured":"Walter JD, Hutter CAJ, Zimmermann I, Earp J, Egloff P, Sorgenfrei M, et al. Synthetic nanobodies targeting the SARS-CoV-2 receptor-binding domain. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.04.16.045419.","journal-title":"bioRxiv"},{"key":"1576_CR249","doi-asserted-by":"publisher","unstructured":"Li T, Cai H, Yao H, Zhou B, Zhang N, Gong Y, et al. A potent synthetic nanobody targets RBD and protects mice from SARS-CoV-2 infection. bioRxiv. 2020. doi.org\/https:\/\/doi.org\/10.21203\/rs.3.rs-75540\/v1. PPR:PPR218472.","DOI":"10.21203\/rs.3.rs-75540\/v1"},{"issue":"1","key":"1576_CR250","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1038\/s41467-020-19204-y","volume":"11","author":"TF Cust\u00f3dio","year":"2020","unstructured":"Cust\u00f3dio TF, Das H, Sheward DJ, Hanke L, Pazicky S, Pieprzyk J, et al. Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2. Nat Commun. 2020;11(1):5588.","journal-title":"Nat Commun"},{"issue":"3","key":"1576_CR251","doi-asserted-by":"publisher","first-page":"e1009328","DOI":"10.1371\/journal.ppat.1009328","volume":"17","author":"H Yao","year":"2021","unstructured":"Yao H, Cai H, Li T, Zhou B, Qin W, Lavillette D, Li D. A high-affinity RBD-targeting nanobody improves fusion partner\u2019s potency against SARS-CoV-2. PLoS pathog. 2021;17(3):e1009328.","journal-title":"PLoS pathog"},{"key":"1576_CR252","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.08.238469","author":"M Schoof","year":"2020","unstructured":"Schoof M, Faust B, Saunders RA, Sangwan S, Rezelj V, Hoppe N, et al. An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.08.08.238469.","journal-title":"bioRxiv"},{"issue":"1","key":"1576_CR253","doi-asserted-by":"publisher","first-page":"17806","DOI":"10.1038\/s41598-020-74761-y","volume":"10","author":"J Dong","year":"2020","unstructured":"Dong J, Huang B, Wang B, Titong A, Gallolu Kankanamalage S, Jia Z, et al. Development of humanized tri-specific nanobodies with potent neutralization for SARS-CoV-2. Sci Rep. 2020;10(1):17806.","journal-title":"Sci Rep"},{"issue":"1","key":"1576_CR254","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1080\/22221751.2020.1768806","volume":"9","author":"J Dong","year":"2020","unstructured":"Dong J, Huang B, Jia Z, Wang B, Gallolu Kankanamalage S, Titong A, Liu Y. Development of multi-specific humanized llama antibodies blocking SARS-CoV-2\/ACE2 interaction with high affinity and avidity. Emerg Microbes Infect. 2020;9(1):1034\u20136.","journal-title":"Emerg Microbes Infect"},{"key":"1576_CR255","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.17.386532","author":"G Ye","year":"2020","unstructured":"Ye G, Gallant JP, Massey C, Shi K, Tai W, Zheng J, et al. The development of a novel nanobody therapeutic for SARS-CoV-2. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.11.17.386532.","journal-title":"bioRxiv"},{"issue":"6","key":"1576_CR256","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","volume":"27","author":"Y Wu","year":"2020","unstructured":"Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, et al. Ying, Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe. 2020;27(6):891-898.e5.","journal-title":"Cell Host Microbe"},{"issue":"1","key":"1576_CR257","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1038\/s41467-020-18387-8","volume":"11","author":"X Chi","year":"2020","unstructured":"Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020;11(1):4528.","journal-title":"Nat Commun"},{"issue":"1","key":"1576_CR258","doi-asserted-by":"publisher","first-page":"1778435","DOI":"10.1080\/19420862.2020.1778435","volume":"12","author":"Z Sun","year":"2020","unstructured":"Sun Z, Chen C, Li W, Martinez DR, Drelich A, Baek DS, et al. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. MAbs. 2020;12(1):1778435.","journal-title":"MAbs"},{"key":"1576_CR259","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2020.1860476","volume":"13","author":"H Kaplon","year":"2021","unstructured":"Kaplon H. Reichert Antibodies to watch in 2021. MAbs. 2021;13:1.","journal-title":"MAbs"},{"key":"1576_CR260","unstructured":"Al-Rubeai M. Antibody expression and production. Cell engineering, vol. 7; 2007."},{"issue":"2","key":"1576_CR261","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.febslet.2013.11.035","volume":"588","author":"AD Bandaranayake","year":"2014","unstructured":"Bandaranayake AD, Almo SC. Recent advances in mammalian protein production. FEBS Lett. 2014;588(2):253\u201360.","journal-title":"FEBS Lett"},{"issue":"12","key":"1576_CR262","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","volume":"36","author":"G Walsh","year":"2018","unstructured":"Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018;36(12):1136\u201345.","journal-title":"Nat Biotechnol"},{"issue":"10","key":"1576_CR263","first-page":"40","volume":"103","author":"KP Jayapal","year":"2007","unstructured":"Jayapal KP, Wlaschin KF, Hu WS, Yap MGS. Recombinant protein therapeutics from CHO cells\u201420 years and counting. Chem Eng Prog. 2007;103(10):40\u20137.","journal-title":"Chem Eng Prog"},{"issue":"2","key":"1576_CR264","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/pr5020020","volume":"5","author":"FM Wurm","year":"2017","unstructured":"Wurm FM, Wurm MJ. Cloning of CHO cells, productivity and genetic stability\u2014a discussion. Processes. 2017;5(2):20.","journal-title":"Processes"},{"key":"1576_CR265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157016381701200305121444","volume":"17","author":"SM Sharker","year":"2020","unstructured":"Sharker SM, Rahman MA. Review of the current methods of Chinese Hamster Ovary (CHO) cells cultivation for production of therapeutic protein. Curr Drug Discov Technol. 2020;17:1.","journal-title":"Curr Drug Discov Technol"},{"key":"1576_CR266","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.copbio.2017.11.015","volume":"51","author":"CC Kuo","year":"2018","unstructured":"Kuo CC, Chiang AW, Shamie I, Samoudi M, Gutierrez JM, Lewis NE. The emerging role of systems biology for engineering protein production in CHO cells. Curr Opin Biotechnol. 2018;51:64\u20139.","journal-title":"Curr Opin Biotechnol"},{"key":"1576_CR267","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/21655979.2019.1682108","volume":"10","author":"S Sarsaiya","year":"2019","unstructured":"Sarsaiya S, Shi J, Che J. Bioengineering tools for the production of pharmaceuticals: current perspective and future outlook. Bioengeneered. 2019;10:469\u201392.","journal-title":"Bioengeneered"},{"issue":"1","key":"1576_CR268","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1080\/21655979.2020.1744266","volume":"11","author":"S P\u00e9rez-Rodriguez","year":"2020","unstructured":"P\u00e9rez-Rodriguez S, Ram\u00edrez-Lira MJ, Trujillo-Rold\u00e1n MA, Valdez-Cruz NA. Nutrient supplementation strategy improves cell concentration and longevity, monoclonal antibody production and lactate metabolism of Chinese hamster ovary cells. Bioengineered. 2020;11(1):463\u201371.","journal-title":"Bioengineered"},{"issue":"5","key":"1576_CR269","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.biotechadv.2016.02.011","volume":"34","author":"A Golabgir","year":"2016","unstructured":"Golabgir A, Gutierrez JM, Hefzi H, Li S, Palsson BO, Herwig C, Lewis NE. Quantitative feature extraction from the Chinese hamster ovary bioprocess bibliome using a novel meta-analysis workflow. Biotechnol Adv. 2016;34(5):621\u201333.","journal-title":"Biotechnol Adv"},{"key":"1576_CR270","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4161\/mabs.1.5.9448","volume":"1","author":"B Kelley","year":"2009","unstructured":"Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs. 2009;1:443\u201352.","journal-title":"MAbs"},{"key":"1576_CR271","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.biologicals.2019.09.006","volume":"62","author":"JT Welch","year":"2019","unstructured":"Welch JT, Arden NS. Considering \u201cclonality\u201d: a regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development. Biologicals. 2019;62:16\u201321.","journal-title":"Biologicals"},{"key":"1576_CR272","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coche.2018.09.005","volume":"22","author":"D Radhakrishnan","year":"2018","unstructured":"Radhakrishnan D, Wells EA, Robinson AS. Strategies to enhance productivity and modify product quality in therapeutic proteins. Curr Opin Chem Eng. 2018;22:81\u20138.","journal-title":"Curr Opin Chem Eng"},{"key":"1576_CR273","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ces.2015.10.029","volume":"141","author":"S Klutz","year":"2016","unstructured":"Klutz S, Holtmann L, Lobedann M, Schembecker G. Cost evaluation of antibody production processes in different operation modes. Chem Eng Sci. 2016;141:63\u201374.","journal-title":"Chem Eng Sci"},{"key":"1576_CR274","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3389\/fimmu.2017.01802","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu Y, Jiang S, Ying T. Single-domain antibodies as therapeutics against human viral diseases. Front Immunol. 2017;8:1802.","journal-title":"Front Immunol"},{"issue":"7","key":"1576_CR275","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.drudis.2016.04.003","volume":"21","author":"S Steeland","year":"2016","unstructured":"Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21(7):1076\u2013113.","journal-title":"Drug Discov Today"},{"issue":"6","key":"1576_CR276","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1002\/bit.22201","volume":"102","author":"EJ Mead","year":"2009","unstructured":"Mead EJ, Chiverton LM, Smales CM, von der Haar T. Identification of the limitations on recombinant gene expression in CHO cell lines with varying luciferase production rates. Biotechnol Bioeng. 2009;102(6):1593\u2013602.","journal-title":"Biotechnol Bioeng"},{"issue":"3","key":"1576_CR277","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.celrep.2020.108274","volume":"33","author":"NC Wu","year":"2020","unstructured":"Wu NC, Yuan M, Liu H, Lee CD, Zhu X, Bangaru S, et al. An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain. Cell Rep. 2020;33(3):108274.","journal-title":"Cell Rep"},{"key":"1576_CR278","doi-asserted-by":"publisher","DOI":"10.1002\/bit.27615","author":"YB Johari","year":"2020","unstructured":"Johari YB, Jaff\u00e9 SRP, Scarrott JM, Johnson AO, Mozzanino T, Pohle TH, et al. Production of trimeric SARS-CoV-2 spike protein by CHO cells for serological COVID-19 testing. Biotechnol Bioeng. 2020. https:\/\/doi.org\/10.1002\/bit.27615.","journal-title":"Biotechnol Bioeng"},{"issue":"11","key":"1576_CR279","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/s41587-020-0732-8","volume":"38","author":"L DeFrancesco","year":"2020","unstructured":"DeFrancesco L. COVID-19 antibodies on trial. Nat Biotechnol. 2020;38(11):1242\u201352.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"1576_CR280","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2020.10245","volume":"324","author":"M Marovich","year":"2020","unstructured":"Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324(2):131\u20132.","journal-title":"JAMA"},{"key":"1576_CR281","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/j.biotechadv.2015.10.015","volume":"33","author":"S Fischer","year":"2015","unstructured":"Fischer S, Handrick R, Otte K. The art of CHO cell engineering: a comprehensive retrospect and future perspectives. Biotechnol Adv. 2015;33:1878\u201396.","journal-title":"Biotechnol Adv"},{"issue":"10","key":"1576_CR282","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.tibtech.2020.07.004","volume":"38","author":"MK Maruthamuthu","year":"2020","unstructured":"Maruthamuthu MK, Rudge SR, Ardekani AM, Ladisch MR, Verma MS. Process analytical technologies and data analytics for the manufacture of monoclonal antibodies. Trends Biotechnol. 2020;38(10):1169\u201386.","journal-title":"Trends Biotechnol"},{"key":"1576_CR283","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bej.2018.09.019","volume":"141","author":"C He","year":"2019","unstructured":"He C, Ye P, Wang H, Liu X, Li F. A systematic mass-transfer modeling approach for mammalian cell culture bioreactor scale-up. Biochem Eng J. 2019;141:173\u201381.","journal-title":"Biochem Eng J"},{"key":"1576_CR284","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/bit.26069","volume":"114","author":"DJ Karst","year":"2017","unstructured":"Karst DJ, Steinebach F, Soos M, Morbidelli M. Process performance and product quality in an integrated continuous antibody production process. Biotechnol Bioeng. 2017;114:298\u2013307.","journal-title":"Biotechnol Bioeng"},{"issue":"8","key":"1576_CR285","first-page":"14","volume":"30","author":"CA Challener","year":"2017","unstructured":"Challener CA. Process Chromatography: continuous Optimization, Improved resin chemistries and customized separation solutions are enabling more efficient separations. BioPharm Int. 2017;30(8):14\u20137.","journal-title":"BioPharm Int"},{"issue":"1","key":"1576_CR286","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12934-019-1059-3","volume":"18","author":"G Bando-Campos","year":"2019","unstructured":"Bando-Campos G, Ju\u00e1rez-L\u00f3pez D, Rom\u00e1n-Gonz\u00e1lez SA, Castillo-Rodal AI, Olvera C, L\u00f3pez-Vidal Y, et al. Recombinant O-mannosylated protein production (PstS-1) from Mycobacterium tuberculosis in Pichia pastoris (Komagataella phaffii) as a tool to study tuberculosis infection. Microb Cell Fact. 2019;18(1):1\u201319.","journal-title":"Microb Cell Fact"},{"issue":"5","key":"1576_CR287","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.biologicals.2016.06.005","volume":"44","author":"N Alt","year":"2016","unstructured":"Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, et al. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44(5):291\u2013305.","journal-title":"Biologicals"},{"issue":"4","key":"1576_CR288","doi-asserted-by":"publisher","first-page":"e2020009399","DOI":"10.1542\/peds.2020-009399","volume":"146","author":"S Bellino","year":"2020","unstructured":"Bellino S, Punzo O, Rota MC, Del Manso M, Urdiales AM, Andrianou X, COVIS-19 WORKING GROUP, et al. COVID-19, disease severity risk factors for pediatric patients in Italy. Pediatrics. 2020;146(4):e2020009399.","journal-title":"Pediatrics"},{"issue":"7838","key":"1576_CR289","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/d41586-020-03496-7","volume":"588","author":"B Nogrady","year":"2020","unstructured":"Nogrady B. How kids\u2019 immune systems can evade COVID. Nature. 2020;588(7838):382.","journal-title":"Nature"},{"key":"1576_CR290","doi-asserted-by":"publisher","DOI":"10.1101\/2021.03.09.434607","author":"AL Cathcart","year":"2021","unstructured":"Cathcart AL, Havenar-Daughton C, Lempp FA, Ma D, Schmid M, Agostini ML, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2021.03.09.434607.","journal-title":"bioRxiv"},{"issue":"2","key":"1576_CR291","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","volume":"13","author":"S Singh","year":"2018","unstructured":"Singh S, Kumar NK, Dwiwedi P, Charan J, Kaur R, Sidhu P, Chugh VK. Monoclonal antibodies: a review. Curr Clin Pharmacol. 2018;13(2):85\u201399.","journal-title":"Curr Clin Pharmacol"},{"key":"1576_CR292","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.31.424987","author":"BB Banach","year":"2021","unstructured":"Banach BB, Cerutti G, Fahad AS, Shen CH, de Souza MO, Katsamba PS, et al. Paired heavy and light chain signatures contribute to potent SARS-CoV-2 neutralization in public antibody responses. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2020.12.31.424987.","journal-title":"bioRxiv"},{"key":"1576_CR293","doi-asserted-by":"publisher","DOI":"10.1101\/2020.10.31.362848","author":"S Miersch","year":"2020","unstructured":"Miersch S, Li Z, Saberianfar R, Ustav M, Case JB, Blazer L, et al. Tetravalent SARS-CoV-2 neutralizing antibodies show enhanced potency and resistance to escape mutations. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.10.31.362848.","journal-title":"bioRxiv"},{"issue":"1","key":"1576_CR294","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-19231-9","volume":"11","author":"NK Hurlburt","year":"2020","unstructured":"Hurlburt NK, Seydoux E, Wan YH, Edara VV, Stuart AB, Feng J, et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat Commun. 2020;11(1):1\u20137.","journal-title":"Nat Commun"},{"key":"1576_CR295","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.31.424729","author":"D Li","year":"2021","unstructured":"Li D, Edwards RJ, Manne K, Martinez DR, Sch\u00e4fer A, Alam SM, et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv. 2021. https:\/\/doi.org\/10.1101\/2020.12.31.424729.","journal-title":"bioRxiv"}],"container-title":["Microbial Cell Factories"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12934-021-01576-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12934-021-01576-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12934-021-01576-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T15:22:06Z","timestamp":1686324126000},"score":1,"resource":{"primary":{"URL":"https:\/\/microbialcellfactories.biomedcentral.com\/articles\/10.1186\/s12934-021-01576-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":295,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1186\/s12934-021-01576-5","relation":{},"ISSN":["1475-2859"],"issn-type":[{"value":"1475-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}